Breaking News Headlines Today | Ground News

See every side of every news story

bariatricnews.net image

News from bariatricnews.net

The Ground News media bias check for bariatricnews.net is unknown. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and AllSides.

Is bariatricnews.net credible or reliable? Our Factuality score answers both of those questions. When it comes to bariatricnews.net, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about bariatricnews.net

Where is bariatricnews.net located?bariatricnews.net's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top bariatricnews.net News

WHO Issues First Guidelines for GLP-1 Obesity Treatments — REUTERS / pwu404

World Health Organization · Geneva

WHO Issues First Guidelines for GLP-1 Obesity Treatments

47% Center coverage: 71 sources

The World Health Organization (WHO) on Monday released its first guidelines on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity, a disease affecting more than 1 billion people globally, which the WHO projects will double by 2030, “without decisive action.”See the Story

GLP-1 Receptor Agonists Likely Have Little or No Effect on Obesity-Related Cancer Risk, Research Shows

GLP-1 · Cambridge

GLP-1 Receptor Agonists Likely Have Little or No Effect on Obesity-Related Cancer Risk, Research Shows

85% Left coverage: 13 sources

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or overweight or obesity.See the Story

Nitinotes Announces First Patient Treated in Pivotal Ease™ Clinical Trial

Nitinotes Announces First Patient Treated in Pivotal Ease™ Clinical Trial

100% Center coverage: 1 sources

Nitinotes announces the first patient treated in the pivotal EASE™ clinical trial, which is evaluating the EndoZip™ automated suturing system for ESG See the Story

Breaking News Topics Related to bariatricnews.net